MCL Literature Feed

This UK real-world, intention-to-treat analysis of brexu-cel confirms high efficacy in infused patients but reveals a 30% attrition rate before infusion and significant non-relapse mortality from infection.

This case report demonstrates delayed Hepatitis B reactivation with acalabrutinib in relapsed MCL, underscoring the need for viral screening and prophylaxis with second-generation BTK inhibitors.

This retrospective study confirms that progression of disease within 24 months (POD24) after initial therapy is a strong negative prognostic marker for overall survival in MCL patients.

This case report describes a rare presentation of intestinal MCL causing ileocecal intussusception in an adult, highlighting a critical differential diagnosis for this acute abdominal condition requiring pathological confirmation.

This case report describes a rare presentation of primary MCL causing life-threatening laryngotracheal stenosis, highlighting the need to consider lymphoma in the differential diagnosis of acute airway obstruction.

This case report links MCL with Henoch-Schönlein purpura and IgA-nephritis, highlighting a rare paraneoplastic syndrome with specific dermatological and renal manifestations for clinicians to recognize.

In young, newly diagnosed MCL, first-line rituximab, bendamustine, and cytarabine (R-BAP) plus a BTK inhibitor improved complete response and PFS over standard R-CHOP/R-DHAP in a real-world setting.

This systematic analysis of MAIT cells across hematological malignancies provides foundational insights into the MCL immune microenvironment, potentially identifying novel biomarkers or immunotherapy targets.

This report describes two contrasting presentations of MCL with plasmacytic differentiation, highlighting the diagnostic challenge of this rare variant which can mimic plasma cell neoplasms, impacting management.

In young, newly diagnosed MCL patients, adding ibrutinib to chemoimmunotherapy improves failure-free survival, establishing a new standard and questioning the necessity of autologous stem cell transplant consolidation.

The phase 3 TRIANGLE trial established that adding ibrutinib to induction/maintenance allows omission of autologous transplant in young, fit MCL patients, providing a new frontline, transplant-free standard.

This case report describes the rare phenomenon of biclonal mantle cell lymphoma, highlighting clonal heterogeneity and evolution which can impact diagnosis, disease progression, and therapeutic resistance.

This preclinical study identifies PLK-1 gene methylation as a key driver of bendamustine resistance, which was reversible with demethylating agents, suggesting a potential new therapeutic strategy.

This review summarizes the clinical data and rationale for targeted agents like BTK and BCL2 inhibitors, highlighting the paradigm shift away from chemotherapy in both relapsed/refractory and frontline MCL.

Transformed MCL with triple-hit genetics (MYC/BCL2/BCL6 rearrangements) can be resistant to BTK inhibitors, identifying a novel genomic mechanism of treatment failure in this aggressive setting.

Gene expression profiling identifies two distinct molecular MCL subtypes, C1 and C2, with C2 showing high proliferation and poor prognosis, providing a powerful new biomarker for risk stratification.

This preclinical study elucidates acalabrutinib's metabolic pathways, identifying reactive intermediates that may explain potential drug-drug interactions, toxicities, or off-target effects in patients with MCL.

This review details the evolution of BTK inhibitors, highlighting improved toxicity with newer agents and the emergence of non-covalent BTKis and novel resistance mutations, impacting MCL treatment sequencing.

This case links progressive necrotizing xanthogranuloma, a rare paraneoplastic syndrome, as the presenting sign of MCL, underscoring the need for hematologic workup for specific skin/ocular findings.

This preclinical study identifies SOX11 as an endogenous inhibitor of SAMHD1, which sensitizes mantle cell lymphoma to cytarabine, suggesting SOX11 status as a predictive biomarker for chemotherapy efficacy.

This case report describes mantle cell lymphoma presenting as multiple colonic polyposis causing obstruction, highlighting a rare gastrointestinal manifestation requiring specific immunohistochemical diagnosis for confirmation.

This B-ALL study reveals MALT1 inhibitors downregulate MYC, providing a novel mechanism and strong rationale for testing this strategy in aggressive, MYC-driven mantle cell lymphoma.

This case report describes indolent mantle cell lymphoma presenting with significant renal disease, highlighting a rare extranodal manifestation as the primary cause of organ dysfunction.

This phase 1/2 trial establishes the safety and efficacy of the BTKi acalabrutinib in Chinese patients with relapsed/refractory MCL, supporting its use in this specific population.

This commentary discusses the zandelisib (PI3Ki) plus zanubrutinib (BTKi) combination, suggesting a potential role for newer, potentially less toxic PI3K inhibitors in relapsed/refractory MCL.

Outpatient autologous stem cell transplantation is a feasible consolidation strategy for advanced MCL in a low-income, Latin American setting, providing important real-world evidence for resource-constrained systems.

This study defines the unique treatment patterns, clinical outcomes, and genomic landscape of Hepatitis B-associated MCL, providing crucial data for managing this complex patient subgroup.

An editor's note highlights a preclinical study where a combined epigenetic therapy shows superior efficacy against MCL cells, suggesting a novel therapeutic strategy for clinical development.

This review positions allogeneic transplant as a key curative option for high-risk (e.g., TP53-mutated) and relapsed/refractory MCL, despite its changing role with the advent of novel therapies.

In a European compassionate use program, pirtobrutinib demonstrated a 67% overall response rate and good safety in heavily pretreated, BTKi-exposed relapsed/refractory MCL, supporting its real-world clinical utility.